Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of YHP2508C and YHR2603 in Healthy Subjects
NCT07584304Phase 1Completed
- Sponsor
- Yuhan
- Start
- Jul 2026
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dapagliflozin (2 arms), sponsored by Yuhan. Primary endpoints: Area under the plasma drug concentration-time curve and Maximum plasma concentration. Started Jul 2026; status: completed.
02
Drugs
dapagliflozin
Beyond the preview
Go deeper on NCT07584304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07584304.